TWD 61.9
(6.17%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -244.57 Million TWD | -1.47% |
2022 | -241.04 Million TWD | -148.37% |
2021 | -97.05 Million TWD | 11.09% |
2020 | -109.15 Million TWD | 16.89% |
2019 | -131.33 Million TWD | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2024 Q2 | -42.96 Million TWD | -16.17% |
2024 Q1 | -36.98 Million TWD | 29.55% |
2023 Q1 | -50.25 Million TWD | -26.92% |
2023 Q4 | -52.49 Million TWD | -33.91% |
2023 Q3 | -39.2 Million TWD | 56.67% |
2023 Q2 | -90.48 Million TWD | -80.05% |
2022 Q4 | -39.59 Million TWD | 0.0% |
2022 FY | - TWD | -148.37% |
2021 FY | - TWD | 11.09% |
2020 FY | - TWD | 16.89% |
2019 FY | - TWD | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
Apex Biotechnology Corp. | 221.06 Million TWD | 210.638% |
Sinphar Pharmaceutical Co.,Ltd. | 582.94 Million TWD | 141.956% |
Panion & Bf Biotech Inc. | 327.21 Million TWD | 174.744% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 473.81 Million TWD | 151.619% |
GenMont Biotech Incorporation | 71.76 Million TWD | 440.788% |
Abnova (Taiwan) Corporation | 81.2 Million TWD | 401.17% |
Adimmune Corporation | -512.42 Million TWD | 52.271% |
Tanvex BioPharma, Inc. | -1.75 Billion TWD | 86.06% |
Polaris Group | -1.38 Billion TWD | 82.398% |
UnicoCell Biomed Co., Ltd. | -56.27 Million TWD | -334.603% |
PELL Bio-Med Technology Co. Ltd. | -353.17 Million TWD | 30.75% |